Accessible Search Form

Skip left side navigation and go to content

NHLBI SBIR/STTR

Omnibus Grant Solicitations for Investigator-Initiated Applications

Please note that the Standard Due Dates have changed to make funding recommendations and awards sooner.

Standard receipt dates are now:
September 5, January 5, April 5 for all applications.
There is no longer a separate receipt date for AIDS and AIDS-related applications.

The NHLBI accepts investigator-initiated grant applications relevant to the NHLBI mission.

  • Phase I, Phase II, and Fast-Track applications are accepted through the Department of Health and Human Services Omnibus SBIR (PA-15-269) and STTR (PA-15-270) Grant Solicitations.
  • You may also apply directly to Phase II if you have preliminary data equivalent to what would normally be done in a Phase I grant (proof-of-concept) through the Direct to Phase II funding opportunity announcement (PAR-14-088).

While the NHLBI has identified topics of special interest, the NHLBI also encourages mission-aligned applications for innovative technologies outside these targeted areas.

For important information about NHLBI's participation in the SBIR/STTR programs, please see the Program Descriptions and Research Topicsimage of PDF icon (1 MB). This document also contains information on submitting budgets exceeding the normal budget guidelines. See the list of topics here, and read Appendix A of the Program Descriptions and Research Topics document for more information.

Small Business Topics of Special Interest for Fiscal Year 2016

Topics are listed here to inform potential applicants about areas of special interest to the NHLBI.

Applications submitted in response to the Omnibus Grant Solicitations are NOT limited to the research and development areas described below.

Instructions for submitting applications in response to the following areas:

  • At the beginning of the title, please include the following four characters: HLS- (Important: according to the NIH's SF424 (R&R) Application Guideimage of PDF icon (2.6 MB). NIH limits title character length to 200 characters including the spaces between words and punctuation. Titles in excess of 200 characters will be truncated).
  • In the first sentence of the abstract, please include the code shown in the last column of the table below. This coding is for internal NHLBI tracking purposes only.
Topic Code

Animal and Cellular Models:

  • for rare non-malignant and  pre-malignant (MDS & MPD) hematologic disorders
  • for complications associated with thrombosis
  • for transfusion of blood products or cell-based  therapies

HLS16-01

Research tools:  Imaging, reagents, assays including microassays, microfluidics, bioinformatics and nanotechnology for investigations of blood diseases, transfusion and cellular therapies 

HLS16-02

Diagnostics: devices, biomarkers, imaging, and assays for non-malignant blood disorders 

HLS16-03

Therapeutics:  drugs, blood product and cellular therapies, and gene therapy for non-malignant blood disorders 

HLS16-04

E-medicine Apps for patients and medical professionals to improve the management of and reduce the impact of non-malignant blood diseases 

HLS16-05

Development of molecular imaging reagents/techniques and nanotechnology-based drug delivery systems which would detect and then allow for specific targeting of lung diseases, such as plexiform lesions in PAH and/or microvascular loci susceptible to rarefaction/pruning in obstructive airway diseases like emphysema, or fibrotic triggers in IPF.

HLS16-06

Development of reagents and methods to identify and isolate stem/progenitor cells, and direct differentiation to specific functional organ units. These reagents may include antibodies for stem/progenitor cell detection and sorting, biomaterials for optimizing the microniches of stem/progenitor cells, as well as methods for 3-D regeneration of tissue.

HLS16-07

Development and validation of techniques(or algorithms) to study the microbiome in situ, including, but not limited to:

  • Sampling the microbiome of different lung or gut segments while minimizing contamination from other locations.
  • Development of an analytical system to study the metabolic products of the lung and gut microbiome from breath condensate

HLS16-08

Characterization and in vivo / in vitro applications of miRNA panels that target lung-resident mesenchymal or fibroblast cells and promote directly or indirectly lung repair/regeneration

HLS16-09

Development of high throughput methods to apply microfluidics technology in discovery of molecular profiles (DNAs, RNAs, proteins, or metabolites) in a large number of sputum or exhaled breath condensate samples collected from lung disease patients.  

HLS16-10

Develop a biocompatible fluid sealant and associated transcatheter technique to permanently seal paravalvular leaks resulting from transcatheter cardiac valve replacement

HLS16-11

Develop smart phone apps and other communication tools to increase accessibility and evaluation of the latest educational materials and trial research on cardiovascular, nutritional and physical activity information for medical professionals and patients (English and non-English speakers)

HLS16-12

Develop a technology that enables immediate, user-friendly measures of average daily sodium intake. These technologies would replace the current standard of 24-hour urine collection

HLS16-13

New animal models for the study of chronic venous insufficiency (CVI) and post-thrombotic syndrome, and innovative approaches for their prevention and treatment.

HLS16-14

Development of mechanical circulatory support devices for individuals with congenital heart disease and single ventricle physiology after Fontan surgical palliation.

HLS16-15

Novel non-invasive strategies that detect early subclinical changes in cardiac structure, function, and /or tissue are needed to improve detection and monitoring of chemotherapy-induced cardiac injury in order to improve cardioprotection and effectiveness of cancer therapeutics.  Strategies that increase sensitivity and precision of existing or enhance imaging technologies with respect to normal and altered cardiac structure, function, energetics, and metabolism are sought.  Pre-clinical or patient studies using molecular changes or biomarkers to enhance early detection of cardiac derangements are also responsive.

HLS16-16

Develop innovative technology and/or service delivery model or design targeted at increasing the adoption, uptake, and sustainability of evidence-based guideline recommendation for the management of heart, lung, blood, and sleep disorders, that include multi-level (health systems, provider, and patient) facets and benefit ethnic/racial minority groups, rural populations, and low socioeconomic groups.

HLS16-17

For questions, contact us.

Last Updated June 2015

Twitter iconTwitter external disclaimer Facebook iconFacebook external disclaimer YouTube iconYouTube external disclaimer Google+ iconGoogle+ external disclaimer